avis

Generalized Myasthenia Gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, impacting an estimated 700,000 people worldwide. The disease can strike anyone at any age but is more frequently seen in young women (age 20 to 30) and men aged 50 and older. In gMG, the communication between the nerves and the muscles, particularly at the neuromuscular junction (NMJ), is disrupted causing muscle weakness. This can result in the loss of control in the eye muscles and a variable combination of the arms, legs, and respiratory muscles. The unpredictable severity and frequency of symptoms in gMG patients can be debilitating, significantly impacting various aspects of day-to-day life.

About the MyClad Phase 3 Clinical Trial Program

The MyClad trial (NCT06463587) is a global Phase 3, randomized, double-blind and placebo-controlled study designed to assess the efficacy and safety of cladribine capsules in 264 patients with gMG
=*=*=*=*=*=
当前为第5/8页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页